Most common treatment-related AEs were in line with the two previously mentioned RC42 phase 1 trials: AST elevation (all grades: 50%, grade ≥ 3: 3%), ALT elevation (all grades: 43%, grade ≥ 3: 3%), leukopenia (all grades: 33%, grade ≥ 3: 7%), neutropenia (all grades: 33%, grade ≥ 3: 10%), numbness (all grades: 23%, grade ≥ 3: 0%). Here, GPT is linked to Decreased total leukocyte count.